In-depth trading ideas

Discover detailed market analysis from traders. See how others approach this instrument, compare different strategies, and discover perspectives that can shape your own view.

AQST potentially forming a monthly inverted head and shoulders NASDAQ:AQST Weekly bollinger bands are very tight as well. The last earnings showed a lot of promise. I should probably wait for the confirmation close above the neckline, but I’ll be buying at least a little bit between $3.96 and $4.15 should the price reach that point. Wish me luck.

Aquestive Therapeutics, Inc. (AQST) Targets Epilepsy And Allergy Aquestive Therapeutics, Inc. (AQST) develops fast-acting, film-based medicines that dissolve on the tongue, making treatment easier for conditions like epilepsy and severe allergies. Its growth comes from new product launches, expanding partnerships, and demand for quick-delivery medicines that avoid injections and work when patients need them most. On the chart, AQST printed a confirmation bar with rising volume as price moved above the 0.236 Fibonacci level and into the momentum zone. A trailing stop can sit just under that 0.236 line using the Fibonacci snap tool, protecting downside while letting momentum carry the move.

by traderspro_charts

AQST – Red Daily Close After Controlled Momentum Run Ticker: AQST (Aquestive Therapeutics) Float: ~54 M shares Market Cap: ≈ 230 M USD Recent Move: +50 % run from $4 → $6 Type: Mid-float red daily close setup 🧩 Thesis AQST has been climbing for several sessions, gaining over 50 % from the $4.00 base. Now the chart printed a red daily close after a multi-day green streak — showing that momentum is slowing and profit-taking pressure is starting to appear. This is a technical fade setup on a mid-float name — not a parabolic blow-off, but a controlled reversal opportunity if the stock fails to reclaim its highs. 🔑 Key Levels $6.10 – 6.20: Local top and risk zone $5.50: First retrace target (≈ 30 % of the run) $5.05: Second target (≈ 50 % retrace) $4.60: Deep-fade target (≈ 70 % retrace) 🎯 Trading Plan Scenario – Red Daily Close Short Confirmed red daily close after an extended move. Watch for a weak open or lower high below $6.00–6.10. Entry: short the rejection under $6.00 once intraday weakness confirms. Risk: stop above $6.20 (previous day’s high). Targets: T1 → $5.50 (cover ⅓) T2 → $5.05 (cover ⅓) T3 → $4.60 (runner if trend accelerates) ⚠️ Risk Notes Float ≈ 54 M → moves are smoother but slower than low-float names. Wait for confirmation of weakness, not just a single red candle. If price reclaims and holds above $6.20, invalidate the setup. 🧭 Summary AQST’s red daily close marks the first sign of exhaustion after a steady uptrend. With moderate float and clean technical structure, the logical fade zone lies between $5.50 – $4.60, depending on how volume contracts. A steady, disciplined short opportunity — not a panic-style move. (Educational use only — not financial advice.)

AQST - RISING PRICES is supported by INCREASING VOLUME AQST - CURRENT PRICE : 5.67 Key Observations : Uptrend Structure – The chart shows a clear uptrend where both highs and lows are moving higher, confirming bullish price action. Volume Confirmation – Rising prices are supported by increasing trading volume, which validates the strength behind the uptrend. OBV Indicator – On-Balance Volume line is trending upward, confirming strong accumulation and participation from buyers. RSI Momentum – RSI is above 70, reflecting strong bullish momentum with no immediate signs of weakness. Overall, the combination of higher highs & higher lows, volume confirmation, and bullish indicators (OBV & RSI) suggest that AQST (Aquestive Therapeutics, Inc.) is well-positioned for further upside in the short to medium term. ENTRY PRICE : 5.47 - 5.67 FIRST TARGET : 6.40 SECOND TARGET : 7.90 SUPPORT : 4.97

Aquestive Therapeutics, Inc. (AQST) Expands Oral Film Tech Aquestive Therapeutics, Inc. (AQST) is a pharmaceutical company focused on developing and commercializing therapies delivered through its proprietary PharmFilm® technology. This platform allows medications to be administered via oral film, improving convenience and patient compliance. Aquestive’s growth is fueled by its pipeline targeting neurological conditions, epilepsy treatments, and its ability to partner with larger pharmaceutical companies to expand applications of its drug delivery system. On the chart, a confirmation bar with rising volume highlights bullish momentum. The price has entered the momentum zone after breaking above the .236 Fibonacci level. A trailing stop can be set just below this Fibonacci mark using the Fibonacci snap tool, helping traders secure profits while staying positioned for more potential gains.

by traderspro_charts

AQST Breakout Setup | ProfittoPath Precision 🚀 📉 Ticker: NASDAQ:AQST (Aquestive Therapeutics Inc.) 🕒 Chart: 30-Min | NASDAQ | June 6, 2025 📊 Setup: Bullish Pennant Breakout + Retest 📌 Trade Plan ✅ Entry: $3.57 (Breakout confirmation) 🛡 Stop-Loss: $3.30 (Below pennant structure) 🎯 Target: $4.04 (Key resistance zone) ⚖️ RRR: ~1:2 — Well-structured breakout setup 💡 Why This Trade? Clean breakout from a tight bullish pennant Price consolidating above key support zone Volume buildup supports breakout move Trend continuation with momentum in favor 🎬 On-Screen Reels Text “AQST Breakout 💥” “Target: $4.04 🚀” 🔖 Top Hashtags #AQST #BreakoutSetup #ProfittoPath #BiotechStocks #TechnicalAnalysis

by ProfittoPath

AQST: Completing to the downside Strength is constructive, but even with only the tail end of this stock's price pattern, it appears price has reached deeply enough back to the upside to expand the upper diagonal enabling the move back down for completion in the target box.

AQST All goes well and as planned for the company AQST all pull backs can be used as new buying opportunities. FDA Type C Meeting The Company also successfully completed a Type C meeting with the FDA that addressed open items from the November 2022 End-of-Phase 2 meeting including addressing (1) the impact of any product hold time, (2) the potential for emesis (vomiting), and (3) the impact of potential mouth conditions such as angioedema (swelling). In response to these questions, the FDA indicated that the Company has “adequately addressed” the FDA’s previous concerns by removing product hold time from the administration instructions and provided additional information on how to characterize emesis in the Company’s NDA submission. Note: Several more steps to do for Anaphylm. Focus and wait.

by chartreader_pro

Aquestive Therapeutics Reports Positive Topline Data from Part 1 AQST: Aquestive Therapeutics, Inc. 2022-02-25 07:00:00 Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine

by RocketTickers

Aquestive Therapeutics Reports Positive Topline Data from Part 1 AQST: Aquestive Therapeutics, Inc. 2022-02-25 07:00:00 Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

by RocketTickers

Aquestive Therapeutics Reports Positive Topline Data from Phase AQST: Aquestive Therapeutics, Inc. 2021-10-25 08:31:00 Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergi

by RocketTickers

AQST 1W Wkly falling wedge setting up for a market structure break and rest to start a 5 wave move possibly. looking for a clearance of the Dec 2, 2019 orderblock for long-term growth

by UnknownUnicorn15994250

AQST breaking downtrend AQST has broken up from an old downtrend. PT1 - 4.69 PT2 - 5.71

AQST definitely negative signal for AQST

AQST PDUFA Approval on the Second You guys know I love biotechs with press releases coming up. I also like to wait to enter until the charts look bullish. Aquestive Therapeutics fell from $8 to $4 in September 2020, and I think they could pull back eventually, regardless of press releases. Now that they have an approval coming up on the second, I expect them to perform phenomenally for the rest of February. They may even push all the way back up to $8. I chose to post now because they look very bullish, at the bottom of the RSI and the MACD looks like it may cross soon. Good Luck!

by Investor4321

AQST Long Long idea. could go to 15 if it gets going

Both its technical analysis and fundamental reports look great. Both its technical analysis and fundamental reports look great. This is a perfect time to buy this stock.

AQST Pattern Bullish Golfing and Line of Support The market found a line of resistance 4,60. Therefore, the market can rising next days.

Short AQST $spy short AQST

by Stockwizard23

$AQST can rise in the next days Contextual immersion trading strategy idea. Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $6,45; stop-loss — $6,00. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!

Best Penny Stocks 🚀 to buy and watch in May 2020 NASDAQ:AQST 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks Our Strategy with this Stock : the company will release the drug for Parkinson disease treatment, The analysts are writing the stock at $17 to drive the sheep to buy the stock , while safe Traders will look for a high price of 6.18 $ . I'm putting two alarms, one at 4.79 to monitor any anticipatory run up. I'm putting two alarms, one at 3.37 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊

by UnknownUnicorn6877177

Aquestive Therapeutics Receives FDA Approval for Exservan™ (rilu AQST: Aquestive Therapeutics, Inc. 2019-11-25 08:00:10 Aquestive Therapeutics Receives FDA Approval for Exservan™ (riluzole) Oral Film

Bad downtrend It is very bad to buy now, maybe can buy in few more months later